Nerandomilast (BI-1015550) is a novel, selective phosphodiesterase 4B (PDE4B) inhibitor being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) . It demonstrates a ninefold preferential inhibitory activity towards PDE4B versus PDE4D, with anti-inflammatory and antifibrotic activity and improved tolerability . Phase III clinical trials (FIBRONEER-IPF and FIBRONEER-ILD) have been conducted, with results announced in 2025 .
Complete series coverage, one-stop procurement. Nerandomilast synthesis involves the coordinated supply of multiple key intermediates. Cosperpharm can simultaneously provide the three core intermediates listed above, helping you reduce supply chain management costs and ensure batch-to-batch consistency and compatibility.
Strict quality control. Each intermediate undergoes HPLC purity verification, appearance inspection, and necessary structural confirmation. Each batch is accompanied by a Certificate of Analysis (COA) to meet the quality requirements of pharmaceutical R&D and production.
Flexible supply scale. From gram-scale research samples to hundred-gram process development, and to kilogram-scale production needs, Cosperpharm can provide packaging specifications and delivery cycles matching your project stage.
Technical documentation support. We can provide COA, MSDS, and customized quality agreements. For regulatory filing needs, DMF-ready documentation packages are available upon request.
To obtain quotations, samples, or technical data for the Nerandomilast (BI-1015550) full series of intermediates, please contact the Cosperpharm sales and technical team. We will respond to your inquiry within 1 business day.
